Test savolitinib plus durvalumab for MET-amplified stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether blocking MET (a cancer growth signal) with savolitinib, combined with durvalumab (an immune treatment), can shrink advanced gastric (stomach) cancer that has worsened after chemotherapy. It may help people whose tumors have MET amplification and measurable disease that can be tracked on scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign an informed consent form and understand the study.
- You are at least 19 years old and weigh over 30 kg.
- Your tumor test shows MET amplification (copy number 4 or higher on local genetic testing).
- Your stomach cancer has progressed after 1 or 2 prior chemotherapy treatments, and you have at least one measurable tumor spot on scans.
- Your overall health is fairly good (ECOG performance 0–1) and you have at least 3 months of expected lifespan.
- Your blood counts and organ functions (bone marrow, liver, kidneys) are within required limits before starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining different drugs before and after surgery can help people with locally advanced stomach cancer that can't be removed right away. The goal is to see which combination works best to shrink the tumor and improve outcomes.
This trial studies savolitinib (an oral MET-targeted medicine) combined with docetaxel (an IV chemotherapy) in people with advanced non-small cell lung cancer (NSCLC) whose tumor has high MET activity. It’s designed to see if this combination can shrink tumors or control the cancer after the first standard treatment.
This trial tests a combination of two targeted drugs (osimertinib and savolitinib) for people with a specific type of advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help patients whose cancer has a low number of MET gene copies.
This trial tests a combination of two drugs, glumetinib and nab-docetaxel, in people with advanced stomach cancer or other solid tumors that have a specific change in the MET gene. The goal is to see if this combination is safe and works better than current treatments.
This trial tests a new combination of chemotherapy and an immunotherapy drug (durvalumab) given before surgery for stomach or gastroesophageal junction cancer. The goal is to see if it shrinks the tumor and improves outcomes.
This trial tests a combination of three drugs—disitamab vedotin, tunlametinib, and a PD-1 antibody—for people with advanced stomach cancer that has HER2 (a protein that helps cancer grow). The goal is to see if this combo can shrink tumors or slow the cancer, and whether it's safe.
Hear when a new Stomach Cancer, Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.